Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

A significant proportion of real-world diabetic macular edema patients are excluded from clinical trials of anti-VEGF therapy due to stringent systemic criteria, disproportionately affecting racial minorities. This study highlights the need for broader inclusion to enhance trial applicability.